Natalia Curto‐García

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Claire Harrison, Jyoti Nangalia, Rebecca H. Boucher et al. · Journal of Clinical Oncology · 2023 · 142 citations · Full text

Medicine, Hematology, Pharmacology +8

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca et al. · Journal of Clinical Oncology · 2023 · 85 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui, Alessandro M. Vannucchi, Alberto Álvarez‐Larrán et al. · Leukemia · 2021 · 82 citations · Full text

Medicine, Hematology, Pharmacology +15

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

Emanuela Sant’Antonio, Paola Guglielmelli, Lisa Pieri et al. · American Journal of Hematology · 2019 · 72 citations · Full text

Medicine, Hematology, Pathology +17

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia

Patrick Harrington, Katie J. Doores, Deepti Radia et al. · British Journal of Haematology · 2021 · 64 citations · Full text

Medicine, Immunology, Oncology +17